253 related articles for article (PubMed ID: 23287362)
1. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Seror R; Richez C; Sordet C; Rist S; Gossec L; Direz G; Houvenagel E; Berthelot JM; Pagnoux C; Dernis E; Melac-Ducamp S; Bouvard B; Asquier C; Martin A; Puechal X; Mariette X;
Rheumatology (Oxford); 2013 May; 52(5):868-74. PubMed ID: 23287362
[TBL] [Abstract][Full Text] [Related]
2. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
3. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
6. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
Gottenberg JE; Merle-Vincent F; Bentaberry F; Allanore Y; Berenbaum F; Fautrel B; Combe B; Durbach A; Sibilia J; Dougados M; Mariette X
Arthritis Rheum; 2003 Jul; 48(7):2019-24. PubMed ID: 12847696
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
13. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
15. [Neurological adverse events under anti-TNF alpha therapy].
Cohen M; Baldin B; Thomas P; Lebrun C
Rev Neurol (Paris); 2012 Jan; 168(1):33-9. PubMed ID: 22098827
[TBL] [Abstract][Full Text] [Related]
16. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
[TBL] [Abstract][Full Text] [Related]
17. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
Fromont A; De Seze J; Fleury MC; Maillefert JF; Moreau T
Cytokine; 2009 Feb; 45(2):55-7. PubMed ID: 19109035
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
